The NAT IVD Products Quarterly Review tracks IVD industry performance as reported and allocates IVD market revenue by company as well as for U.S. and international markets with three-year revenue trends. The report, along with e-mail/fax alerts on any "breaking" news, enables managers to have an up-to-date picture of the dynamic NAT market. This report also enables clients to keep abreast of new product and licensing activity (including summaries of pertinent conferences), identify trends, and assess competitors' strengths and weaknesses on a quarterly basis. As the NAT market evolves, so will the NAT IVD Products Quarterly Review, tracking new companies, new tests, and new technologies, keeping managers ahead of the learning curve.
In addition to tracking quarterly IVD industry performance by company for the U.S. versus international segments, BBC segments the NAT market for clinical diagnostic infectious disease, cancer, genetic testing, and blood donor screening, each of which is addressed separately. The report also includes the following information for the NAT market:
Moreover, the report contains a "year-end" outlook section, which provides a near-term outlook for the NAT market/company performance including the assumptions built into the forecast. Companies of interest other than the current "Top Six" IVD companies will also be included on an ad hoc basis.
For clients who have no strategic interest in the Blood Processing (blood donor screening) market segment (i.e., Blood Processing and Chiron sections), an optional version of the NAT Quarterly is available at a lower price.